This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
However, there has not been a clinicaltrial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinicaltrial for cannabis as a migraine treatment is underway. This is exciting news for individuals who suffer from this debilitating condition.
The majority of people who use the cannabinoid cannabigerol (CBG) for medical reasons find it to be helpful or very helpful in treating a variety of health conditions, according to the findings of a recent survey. No clinicaltrial was used in the compilation of the study. who have used it to treat anxiety.
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com.
” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.
Silo Pharma’s notice of allowance paves the way toward clinicaltrials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.
As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. THC, the psychoactive component of cannabis, has analgesic properties that can help manage chronic pain conditions, such as neuropathic pain and arthritis.
(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinicaltrial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study. The average age was 80.9
Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. The answer: Maybe!
CBN’s ability to target CB2 receptors, in comparison to THC (which prefers the CB1 receptor), gives it better credibility in treating autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. What can the current clinicaltrials tell us?
Various clinicaltrials are investigating the effectiveness of cannabis and its components in treating PTSD symptoms. Many patients report significant improvements in their PTSD symptoms with cannabis use and Florida has listed PTSD as a qualifying condition in order to obtain a Medical Marijuana card. Fernando Fandiño-Sende.
Clinicaltrials into cannabis’ potential as an opioid replacement are well underway in South Africa. Quite frankly, the clinicaltrials couldn’t have come at a better time. About the Opioid Epidemic. I don’t think it works for severe pain. Together, they work very well.
Company has also initiated preclinical studies aimed at treating psychologic and neurologic conditions. PsyBio intends to continue utilizing its resources to rapidly develop and test new drug candidates within this and other psychedelic categories in anticipation of launching future clinicaltrials.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
Psilocybin , a psychedelic compound found in a variety of mushrooms, has long been used as a tool to mitigate depression despite the limited amount of research on its efficacy and safety. While 233 participants might sound low, it is still the largest number of humans to participate in a psilocybin-based clinicaltrial.
” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.
These companies faced administrative actions by the FTC for “making a wide range of scientifically unsupported claims about their ability to treat serious health conditions,” such as cancer, Alzheimer’s disease, and pain relief. The warning letters address the illegal marketing of unapproved CBD products claiming to treat medical conditions.
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. The results of the clinicaltrial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).
And it further reinforces the need to carry out clinicaltrials to determine the safety and efficiency of using psilocybin to treat OCD. Current approaches to treat this condition are helpful but do not always provide full relief. In some cases, these patients are prone to depression and suicide.
Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Looking ahead, the future of medical cannabis in PTSD treatment hinges on overcoming these challenges.
Living with chronic conditions such as Multiple Sclerosis (MS) is profoundly challenging and impacts various aspects of daily life. of medical marijuana as a viable treatment option for certain conditions, including Multiple Sclerosis (MS), leading to increased advocacy for uniform regulations and broader accessibility.
Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.
Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis. Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinicaltrials are finding value in the company’s offerings.
Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Parkinson’s disease and cannabis.
However, there is a tradeoff between effectiveness and safety. Scientists have also studied combinations of THC and CBD, such as Sativex clinicaltrials that show patients’ marked improvement in sleep. Nearly all diseases, particularly chronic conditions like diabetes, require healthy sleep for patient improvement.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.
According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. 9 -Tetrahydrocannabinol (THC) in patients with chronic pain. 9 -THC: 0.5mg, 1mg, or a placebo. ?
More than half the states in the country have now legalized medical cannabis for patients with qualifying conditions and several more have gone so far as to legalize recreational marijuana for adults. Children who suffer from these conditions generally experience social and developmental delays due to constant seizures.
In this article, we explore the role of medical marijuana in addressing insomnia, examining its effectiveness, safety considerations, legal aspects, and practical considerations for patients and healthcare providers. It can be caused by a variety of factors, including medical conditions, psychological issues, or environmental factors.
One study supporting the efficacy of cannabinoids is in the Journal of Pain and Symptom Management, titled, “Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract in Patients with Intractable Cancer-Related Pain.”
Technically speaking, it’s not produced by the plant, but is rather a degradation product of delta-9-THC, often as a result of aging and storage conditions. When it comes to safety, the two main factors to consider are production (standards and regulation) and research. Delta-8-THC vs delta-9-THC: How it works and how it feels.
“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinicaltrials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” ” About PsyBio Therapeutics Corp.
#image_title Cannabis has been increasingly studied for its potential therapeutic benefits in various medical conditions, including skin disorders and skin cancer. Cannabinoids , particularly cannabidiol (CBD), have shown anti-inflammatory effects that can be beneficial for skin conditions such as acne, psoriasis, and eczema.
Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. The respondents ranged in age from 19 to 81, and 50% identified as White, 20% as Latino, 12% as Asian, and 10% as Black.
We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. President, Director and Chief Medical Officer of MyMD. “We
Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.
CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.
Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinicaltrials. However, we need rigorous clinicaltrials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.
Medical marijuana has shown potential in treating a wide range of medical conditions, including epilepsy. Epilepsy and MMJ: A Patient’s Perspective For individuals living with epilepsy, finding an effective treatment is often a journey marked by trial and error.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content